Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
SupportTel Aviv, Israel
Alon Blue Square Israel has issued bonds worth US$81 million
Alon Blue Square Israel Ltd. has completed a fundraising to refinance and develop the company.Learn more
Westminster Homecare has been acquired by Care at Home
The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.Learn more
RVC Medical IT has been acquired by NEXUS AG
Main Capital Partners B.V. has sold RVC Medical IT B.V. to NEXUS AG.Learn more